By targeting circulating ANGPTL3, everolimus has been shown to effectively reduce levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and TG in both healthy individuals and patients with familial hypercholesterolemia. This evidence concerns the gene ANGPTL3 and familial hypercholesterolemia.